NASDAQ:IMVT

Immunovant Competitors

$15.42
-0.46 (-2.90 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$15.25
Now: $15.42
$15.93
50-Day Range
$13.08
MA: $15.87
$17.17
52-Week Range
$11.80
Now: $15.42
$53.75
Volume559,497 shs
Average Volume1.47 million shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Immunovant (NASDAQ:IMVT) Vs. KOD, ADPT, VIR, CBPO, ALLO, and BEAM

Should you be buying IMVT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Immunovant, including Kodiak Sciences (KOD), Adaptive Biotechnologies (ADPT), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), and Beam Therapeutics (BEAM).

Kodiak Sciences (NASDAQ:KOD) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Kodiak Sciences and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
ImmunovantN/A-34.80%-32.38%

Analyst Ratings

This is a summary of recent ratings for Kodiak Sciences and Immunovant, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences17402.25
Immunovant011402.93

Kodiak Sciences presently has a consensus price target of $129.9091, indicating a potential upside of 14.39%. Immunovant has a consensus price target of $45.60, indicating a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Kodiak Sciences.

Earnings & Valuation

This table compares Kodiak Sciences and Immunovant's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-91.91
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01

Kodiak Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 40.2% of Immunovant shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 0.2% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Kodiak Sciences beats Immunovant on 6 of the 10 factors compared between the two stocks.

Immunovant (NASDAQ:IMVT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Insider & Institutional Ownership

40.2% of Immunovant shares are owned by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are owned by institutional investors. 0.2% of Immunovant shares are owned by insiders. Comparatively, 22.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Immunovant and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunovantN/A-34.80%-32.38%
Adaptive Biotechnologies-132.32%-20.15%-13.09%

Valuation and Earnings

This table compares Immunovant and Adaptive Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01
Adaptive Biotechnologies$85.07 million68.78$-68,610,000.00($1.01)-41.61

Immunovant has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Immunovant and Adaptive Biotechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunovant011402.93
Adaptive Biotechnologies02402.67

Immunovant currently has a consensus price target of $45.60, indicating a potential upside of 192.68%. Adaptive Biotechnologies has a consensus price target of $61.40, indicating a potential upside of 46.71%. Given Immunovant's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunovant is more favorable than Adaptive Biotechnologies.

Vir Biotechnology (NASDAQ:VIR) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

54.5% of Vir Biotechnology shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 37.2% of Vir Biotechnology shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
ImmunovantN/A-34.80%-32.38%

Valuation & Earnings

This table compares Vir Biotechnology and Immunovant's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million726.46$-174,680,000.00($5.76)-7.97
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01

Immunovant has lower revenue, but higher earnings than Vir Biotechnology. Immunovant is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vir Biotechnology and Immunovant, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Immunovant011402.93

Vir Biotechnology currently has a consensus target price of $66.00, indicating a potential upside of 43.73%. Immunovant has a consensus target price of $45.60, indicating a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Vir Biotechnology.

Summary

Immunovant beats Vir Biotechnology on 9 of the 12 factors compared between the two stocks.

China Biologic Products (NASDAQ:CBPO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

34.8% of China Biologic Products shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 2.7% of China Biologic Products shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares China Biologic Products and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
ImmunovantN/A-34.80%-32.38%

Valuation & Earnings

This table compares China Biologic Products and Immunovant's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.24$138.81 million$4.2827.63
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01

China Biologic Products has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for China Biologic Products and Immunovant, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
Immunovant011402.93

Immunovant has a consensus target price of $45.60, indicating a potential upside of 192.68%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than China Biologic Products.

Summary

China Biologic Products beats Immunovant on 8 of the 11 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Allogene Therapeutics and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
ImmunovantN/A-34.80%-32.38%

Valuation & Earnings

This table compares Allogene Therapeutics and Immunovant's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.73
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Allogene Therapeutics and Immunovant, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
Immunovant011402.93

Allogene Therapeutics currently has a consensus target price of $52.0833, indicating a potential upside of 60.55%. Immunovant has a consensus target price of $45.60, indicating a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Allogene Therapeutics.

Summary

Immunovant beats Allogene Therapeutics on 6 of the 10 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Beam Therapeutics and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
ImmunovantN/A-34.80%-32.38%

Valuation and Earnings

This table compares Beam Therapeutics and Immunovant's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00227,047.22$-78,330,000.00($14.05)-5.17
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01

Immunovant has lower revenue, but higher earnings than Beam Therapeutics. Immunovant is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Beam Therapeutics and Immunovant, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Immunovant011402.93

Beam Therapeutics presently has a consensus target price of $96.00, suggesting a potential upside of 31.18%. Immunovant has a consensus target price of $45.60, suggesting a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Beam Therapeutics.

Summary

Immunovant beats Beam Therapeutics on 8 of the 12 factors compared between the two stocks.


Immunovant Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$114.89-0.7%$5.88 billionN/A-49.52
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$42.03-2.4%$5.85 billion$85.07 million-44.24
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.92-1.9%$5.76 billion$8.09 million-19.46Analyst Downgrade
Insider Selling
News Coverage
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44-1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.69-1.5%$4.54 billion$20,000.00-5.17
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14-1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$70.01-5.1%$3.43 billionN/A-40.24Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01-1.6%$3.25 billion$125.57 million-42.70Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.60-3.5%$2.95 billionN/A0.00News Coverage
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67-18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49-0.7%$2.10 billion$31.43 million-5.13Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.30-1.0%$1.97 billionN/A-11.36Decrease in Short Interest
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.28-5.1%$1.90 billion$44.67 million-2.58
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66-0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33-0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51-3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55-1.1%$1.40 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65-10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77-0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Up
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.